8-K: LENSAR Q2 2025 Results Show Growth Amid Alcon Merger

LENSAR, Inc. reported strong second quarter 2025 operational performance with increased revenue and procedure volumes, as its proposed merger with Alcon progresses towards an expected year-end close.

Summary

• Total revenue for Q2 2025 was $13.9 million, a 10% increase from $12.6 million in Q2 2024.
• Worldwide procedure volumes increased by 23% in Q2 2025 compared to Q2 2024.
• 18 ALLY Robotic Cataract Laser Systems were placed in Q2 2025, with an additional 18 systems in backlog as of June 30, 2025.
• The ALLY installed base grew 107% and the total combined installed base reached approximately 410 systems, a 23% increase over Q2 2024.
• Net loss for Q2 2025 significantly decreased to $1.8 million, or ($0.15) per common share, from $9.0 million, or ($0.79) per common share, in Q2 2024, primarily due to a change in warrant liability.
• The proposed merger with Alcon was overwhelmingly approved by stockholders and is expected to close by the end of 2025, pending FTC review.

Sentiment

Score: 8

Explanation: The company demonstrated strong operational growth with increased revenue, procedure volumes, and system placements. The significant reduction in net loss is a positive financial indicator. The overwhelming stockholder approval for the Alcon merger signals confidence in the strategic direction, and the expectation of a year-end close provides clarity. While SG&A increased due to merger costs, this is a temporary expense related to a potentially transformative event.

Positives

• Total revenue increased by 10% to $13.9 million in Q2 2025.
• Worldwide procedure volumes increased significantly by 23% over Q2 2024.
• 18 ALLY Systems were placed in Q2 2025, demonstrating strong commercial momentum.
• The ALLY installed base grew by 107% year-over-year.
• Total installed base of LENSAR Laser Systems and ALLY Systems increased by 23% to approximately 410 systems.
• Net loss decreased substantially to $1.8 million in Q2 2025 from $9.0 million in Q2 2024.
• EBITDA improved to ($0.9) million in Q2 2025 from ($8.3) million in Q2 2024.
• The proposed merger with Alcon received overwhelming stockholder approval (over 99% of votes cast in favor).
• Recurring revenue percentage increased to 82% in Q2 2025 from 79% in Q2 2024.

Negatives

• Selling, general and administrative expenses increased by 72% to $11.7 million in Q2 2025, primarily due to $4.2 million in acquisition-related costs for the Alcon merger.
• Adjusted EBITDA remained negative at ($0.3) million for Q2 2025, a decrease from $30,000 in Q2 2024.
• Cash, cash equivalents, and investments decreased to $20.3 million as of June 30, 2025, from $22.5 million at December 31, 2024, despite a $10.0 million deposit from Alcon.

Risks

• The proposed merger with Alcon may not be completed in a timely manner or at all, including risks related to obtaining required regulatory approvals, potential delays, or unanticipated conditions.
• Failure to realize the anticipated benefits of the proposed merger.
• The possibility of competing offers or acquisition proposals for the Company.
• Risk that the milestone related to the contingent value right is not achieved.
• The possibility that any or all conditions to the merger's consummation may not be satisfied or waived, including failure to receive required regulatory approvals or the imposition of conditions, limitations, or restrictions on such approvals.
• The occurrence of any event, change, or circumstance that could lead to the termination of the merger, potentially requiring LENSAR to pay a termination fee or other expenses.
• The effect of the merger announcement or its pendency on the Company's ability to retain and hire key personnel, or its operating results and business generally.
• Potential for unknown, probable, or unestimable liabilities related to the merger, or unexpected costs, charges, or expenses.
• Diversion of management's time and attention to issues related to the merger.
• Significant transaction costs in connection with the merger.
• Adverse consequences of legal proceedings instituted against the Company following the merger announcement.
• The Company's stock price may decline significantly if the merger is not consummated.

Future Outlook

The proposed merger with Alcon is progressing, having received overwhelming stockholder approval, and is expected to close by the end of 2025, pending ongoing review by the U.S. Federal Trade Commission.

Management Comments

• Our second quarter results reflect the continued, strong momentum of ALLY with 18 systems placed in the quarter and an additional 18 systems in backlog.
• We continued to see strong procedure growth, with worldwide procedure volumes increasing 23% over second quarter 2024 levels.
• In parallel with our strong operational performance, the proposed merger with Alcon continues to progress.
• The proposed merger was overwhelmingly approved at a special meeting of our stockholders held last month. At that meeting, over 80% of our outstanding shares were voted, with over 99% of the votes cast in favor of the transaction.
• We are currently working cooperatively with the U.S. Federal Trade Commission to respond to its request for additional information and continue to expect the transaction to close by the end of this year.
• On behalf of the entire management team, I want to extend a thank you to our stockholders for their overwhelming support of this transformative deal.

Industry Context

LENSAR operates in the medical technology sector, specifically focusing on advanced robotic laser solutions for cataract treatment. The strong growth in ALLY system placements and procedure volumes indicates robust demand within the ophthalmology market for advanced surgical technologies. The proposed acquisition by Alcon, a global leader in eye care, signifies a consolidation trend and validates LENSAR's technological advancements, potentially enhancing its market reach and integration into a larger, more established eye care portfolio.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to benchmark LENSAR's performance against industry standards. However, the 23% increase in worldwide procedure volumes and 107% growth in the ALLY installed base suggest strong adoption rates for its innovative robotic cataract laser system, which could be considered above average for a specialized medical device in a mature market, though direct comparisons are not provided.

Legal Proceedings

• Adverse consequences of legal proceedings instituted against the Company following the announcement of the merger (mentioned as a risk).

Stakeholder Impact

• Shareholders: Overwhelmingly approved the Alcon merger, indicating potential for value realization from the transaction. The stock price may decline significantly if the merger is not consummated.
• Employees: Potential impact on retention and hiring of key personnel due to the merger's announcement or pendency.
• Customers: Continued strong placement of ALLY systems and increased procedure volumes indicate positive customer adoption and utilization of LENSAR's technology.

Next Steps

• Continue working cooperatively with the U.S. Federal Trade Commission to respond to its request for additional information regarding the Alcon merger.
• Close the proposed merger with Alcon by the end of 2025.
• File the Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, with the SEC.

Key Dates

Recommendation

The company reported robust operational growth with significant increases in revenue, procedure volumes, and installed base for its ALLY system, demonstrating strong market adoption. The substantial reduction in net loss is a positive financial turnaround. Crucially, the proposed acquisition by Alcon, a major industry player, has received overwhelming stockholder approval and is on track for a year-end close. This merger is highly transformative, offering potential for significant shareholder value realization and integration into a larger, more stable entity. While there are merger-related costs and regulatory hurdles, the progress and positive operational metrics make this an attractive investment, especially given the potential for a premium upon acquisition.

Keywords

Cataract surgery, Robotic laser systems, ALLY System, Medical technology, Ophthalmology, SEC filing, Financial results, Merger and acquisition, Alcon, LNSR